Project Grant R01AI183590

Award Date 6/11/24
Completion Date 4/30/29
Dollars Obligated $2.9M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $147,656 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Colorado-Denver. The project aims to elucidate the mechanisms driving the development of chronic Chikungunya virus (CHIKV) arthritis, a debilitating condition affecting up to 50% of CHIKV patients. The research will define the viral reservoir in macrophages, assess mechanisms driving pro-inflammatory...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will fund research to determine the mechanisms by which the Ross River virus (RRV) and Chikungunya virus (CHIKV) cause acute and chronic muscle damage and dysfunction. The $640,905 award, effective May 15, 2025 through April 30, 2030, will support a collaborative effort between a skeletal muscle...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $782,871 in funding to the University of Colorado-Denver to conduct research on the immune evasion mechanisms of arthritogenic alphavirus infections, such as Chikungunya and Ross River viruses. The key objectives of this 5-year research project are to: 1) investigate how type I interferon signaling in...
This Project Grant award, in the amount of $506,530, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The primary objective of this 2-year grant is to define the mechanisms by which antibodies can block cell-to-cell transmission of alphavirus infections, such as chikungunya virus (CHIKV) and Mayaro virus (MAYV). The research will: 1) Determine how antibodies target viral envelope proteins...
This federal Project Grant award of $2,370,939 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research into the molecular mechanisms governing chikungunya virus (CHIKV) binding, tropism, and pathogenesis. The primary objectives are to define the specific heparan sulfate (HS) structures required for CHIKV attachment and infection of target cells, identify the viral E2 protein residues...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a 2-year, $544,500 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to the Texas Biomedical Research Institute to characterize a novel mouse model for studying the neurological impacts of Chikungunya virus infection. The research aims to determine the mechanisms by which Chikungunya virus infects the brain and evaluate whether the mouse model develops the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $843,620 to Albert Einstein College of Medicine to develop new broadly inhibitory antibody therapies against alphaviruses, a group of mosquito-transmitted viruses that can cause severe musculoskeletal disease and neurological conditions. The key objectives are to: 1) engineer Fc mutations into broadly protective antibodies to improve their in...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,969 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to L2 Diagnostics LLC, a for-profit biomedical research company based in Woodbridge, Connecticut. The grant is focused on evaluating a mosquito salivary protein, AGBR1, as a vaccine candidate against Chikungunya virus, which is transmitted by Aedes mosquitoes and can cause debilitating joint pain. Under this two-year...
The University of Texas Medical Branch at Galveston (UTMB) was awarded a $915,178 Project Grant under the National Institute of Allergy and Infectious Diseases' (NIAID) Allergy and Infectious Diseases Research program (CFDA 93.855). The funding will support the development and evaluation of novel hamster models to study the pathogenesis of chikungunya virus (CHIKV) infection, with a focus on understanding the mechanisms underlying CHIKV-induced chronic arthralgia and vertical transmission. The...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $170,640 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University in St. Louis. The grant supports a career development program for Dr. Saravanan Raju, M.D., Ph.D., to establish an independent research career as an academic physician-scientist. The proposed research aims to study the basis of broad and durable immunity to arthritogenic alphaviruses,...

PATHOGENESIS OF ALPHAVIRUS INDUCED CHRONIC ARTHRITIS AND MYOSITIS - SUMMARY. CHIKUNGUNYA VIRUS (CHIKV) IS AN EMERGING MOSQUITO-TRANSMITTED ALPHAVIRUS THAT CAUSES AN ABRUPT ONSET OF FEVER WITH SEVERE JOINT AND MUSCLE PAIN. IN A SIGNIFICANT FRACTION OF PATIENTS, CHRONIC AND DEBILITATING ARTHRITIS CAN DEVELOP AND PERSIST FOR MONTHS TO YEARS, WITH RECENT EPIDEMIOLOGICAL PROJECTIONS SUGGESTING THERE ARE MORE THAN 400,000 PATIENTS IN THE WESTERN HEMISPHERE ALONE WITH CHRONIC CHIKV MUSCULOSKELETAL DISEASE. PATIENTS AFFECTED BY CHRONIC CHIKV DISEASE SHOW ELEVATED SYNOVIAL PROINFLAMMATORY CYTOKINES AND INFILTRATING CELLS INCLUDING MONOCYTES AND CD4+ T CELLS. IN ADDITION, PERSISTENT CHIKV RNA IS DETECTED IN HUMAN PATIENTS, NON-HUMAN PRIMATES, AND MICE FOR MONTHS TO YEARS AFTER INFECTION. TO IDENTIFY THE CELLS THAT HARBOR THIS RNA DURING THE CHRONIC PHASE OF DISEASE, WE RECENTLY ENGINEERED A RECOMBINANT CHIKV TO EXPRESS CRE RECOMBINASE AND DEMONSTRATED THAT THE INFECTION OF TDTOMATO REPORTER MICE RESULTED IN PERSISTENT TDTOMATO+ CELLS. TO DATE, OUR ANALYSIS HAS REVEALED THAT FIBROBLASTS AND MACROPHAGES ARE KEY CELL TYPES THAT HARBOR VIRAL RNA IN THE CHRONIC PHASE. THEREFORE, THIS SYSTEM ALLOWS US TO TEST THE HYPOTHESIS THAT DURING CHRONIC DISEASE, A SUBSET OF CHIKV INFECTED CELLS SURVIVE INFECTION AND HARBOR PERSISTENT, NON-PRODUCTIVELY REPLICATING VIRAL RNA THAT FUNCTIONS AS A PATHOGEN ASSOCIATED MOLECULAR PATTERN (PAMP) TO DRIVE PERSISTENT INFLAMMATION. THE PREMISE OF THIS PROPOSAL IS TO UTILIZE THIS CHIKV LINEAGE TRACING SYSTEM IN A MURINE MODEL OF CHIKV ARTHRITIS TO IDENTIFY, ISOLATE, AND CHARACTERIZE THE CELLS THAT ARE INFECTED, SURVIVE CHIKV INFECTION, AND HARBOR VIRAL RNA. WE WILL TEST THE HYPOTHESIS THAT THIS PERSISTENT RNA ACTIVATES PATTERN RECOGNITION RECEPTORS DURING ACUTE AND CHRONIC DISEASE DRIVING INFLAMMATORY PHENOTYPES IN BOTH MACROPHAGES AND FIBROBLASTS. THESE STUDIES WILL PROVIDE IMPORTANT NEW INSIGHT INTO THE PATHOGENESIS OF CHRONIC CHIKV ARTHRITIS AND POSSIBLY CREATE NEW AVENUES FOR THERAPEUTIC INTERVENTIONS.

Posted 6/11/24, 12:00 AM